Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

NCT01333423 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Liposomal Doxorubicin
DRUG: Seliciclib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]